| CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression K Fousek, J Watanabe, SK Joseph, A George, X An, TT Byrd, JS Morris, ... Leukemia 35 (1), 75-89, 2021 | 137 | 2021 |
| Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma M Hegde, SK Joseph, F Pashankar, C DeRenzo, K Sanber, S Navai, ... Nature communications 11 (1), 3549, 2020 | 117 | 2020 |
| Construction of stable packaging cell lines for clinical lentiviral vector production KS Sanber, SB Knight, SL Stephen, R Bailey, D Escors, J Minshull, ... Scientific reports 5 (1), 9021, 2015 | 114 | 2015 |
| Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells K Sanber, B Savani, T Jain British journal of haematology 195 (5), 660-668, 2021 | 57 | 2021 |
| Targeting hydrogen sulphide signaling in breast cancer RA Youness, AZ Gad, K Sanber, YJ Ahn, GJ Lee, E Khallaf, HM Hafez, ... Journal of advanced research 27, 177-190, 2021 | 52 | 2021 |
| Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas SA Navai, C Derenzo, S Joseph, K Sanber, T Byrd, H Zhang, M Mata, ... Cancer Research 79 (13_Supplement), LB-147-LB-147, 2019 | 48 | 2019 |
| Lentivector producer cell lines with stably expressed vesiculovirus envelopes M Tijani, AM Munis, C Perry, K Sanber, M Ferraresso, T Mukhopadhyay, ... Molecular Therapy-Methods & Clinical Development 10, 303-312, 2018 | 14 | 2018 |
| Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020; 11 (1): 3549 M Hegde, SK Joseph, F Pashankar, C DeRenzo, K Sanber, S Navai J Immunother Cancer: first published as 10, 0 | 9 | |
| Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book: A Practical Guide DW Lee, NN Shah Elsevier Health Sciences, 2019 | 7 | 2019 |
| Effect of interleukins on antibody production by Epstein-Barr virus transformed B cells AI Ali, YR Badran, MR Hassuneh, KS Sanber, SI Ismail Monoclonal antibodies in immunodiagnosis and immunotherapy 34 (3), 162-168, 2015 | 5 | 2015 |
| Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease K Sanber, K Ye, HL Tsai, M Newman, JA Webster, I Gojo, G Ghiaur, ... Leukemia & Lymphoma 64 (4), 846-855, 2023 | 4 | 2023 |
| Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas SA Navai, C Derenzo, S Joseph, K Sanber, T Byrd, H Zhang, M Mata, ... Cancer Research 79 (13), 2019 | 4 | 2019 |
| Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages A Ly, K Sanber, HL Tsai, A Ondo, K Mooney, A Shedeck, J Baker, ... British journal of haematology, 0 | 4 | |
| I-PASS Illness Severity Identifies Patients at Risk for Overnight Clinical Deterioration C Shah, K Sanber, R Jacobson, B Kaul, S Tuthill, V Hemmige, E Guy, ... Journal of graduate medical education 12 (5), 578-582, 2020 | 3 | 2020 |
| Production of self-inactivating lentiviral vectors by constitutive packaging cell lines for gene therapy clinical applications KSR Sanber UCL (University College London), 2015 | 2 | 2015 |
| A clinical-grade constitutive packaging cell line for the production of self-inactivating lentiviral vectors S Knight, K Sanber, S Stephen, M Ferraresso, R Baley, D Escors, ... Human Gene Therapy 25 (11), A101-A102, 2014 | 2 | 2014 |
| Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer K Sanber, S Rosner, PM Forde, KA Marrone BioDrugs, 1-17, 2023 | 1 | 2023 |
| P572: VENETOCLAX AND HYPOMETHYLATING AGENT COMBINATIONS FOR THE TREATMENT OF ADVANCED MYELOPROLIFERATIVE NEOPLASMS AND ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY DISEASE K Sanber, K Ye, HL Tsai, M Newman, A Ambinder, A DeZern, T Jain HemaSphere 6, 471-472, 2022 | 1 | 2022 |
| Modulation of inhibitory receptor signaling pathways improves CAR T cell activity against glioblastoma K Sanber, Z Nawas, V Salsman, A Gad, P Mathew, D Landi, C Lee, ... Cytotherapy 22 (5), S19-S20, 2020 | 1 | 2020 |
| Outpatient CD28‐costimulated CAR T‐cells for B‐cell malignancies with CNS involvement K Sanber, A Ly, A Ondo, K Mooney, J Baker, A Shedeck, ... American Journal of Hematology, 2023 | | 2023 |
